Inspire gets $75M injection from Warburg Pincus

Warburg Pincus is buying $75 million worth of Inspire Pharmaceuticals' stock. The private equity group paid a five percent premium for the shares, which immediately pushed up the value of the company's stock by 14 percent. For Inspire, the fresh injection of capital will help fund late-stage studies while launching the newly-approved AzaSite for bacterial conjunctivitis.

- check out the release
- read the AP report

Related Articles:
Inspire wins feds approval of eye infection therapy. Report
Inspire licenses anti-infective for $13M upfront. Report
Side effects prompt Inspire to shutter trial. Report
Inspire shares plunge after FDA finds data insufficient. Report